Parkinson's disease (PD) is a progressive neurological disorder, in which dopaminergic
midbrain neurons degenerate, leading to dopamine depletion that is associated with …

Parkinson's disease (PD) is the second most common progressive neurodegenerative
disease, affecting 1–2% of people over 65. The classic motor symptoms of PD result from …

Cell replacement therapy (CRT) is a promising treatment for degenerative disorders, such as
Parkinson's disease (PD). However, CRT is in general hindered by poor graft survival …

Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder
symptomatically characterized by resting tremor, rigidity, bradykinesia, and gait impairment …

Parkinson's disease is a neurodegenerative disease, the treatment of which is mainly
centred around supplementation of dopamine. Additional targets have been identified and …

Parkinson's disease (PD) affects 10 million patients worldwide, making it the second most
prevalent neurodegenerative disease. Motor symptoms emerge from the loss of dopamine in …

Parkinson's disease is the second most common neurodegenerative disorder. It is
characterised by a typical movement disorder that occurs in part because of the selective …

The dopamine precursor, levodopa, remains the “gold standard” treatment for Parkinson's
disease, and, although it provides superlative efficacy in the early stages of the disease, its …

Current approaches to cell replacement therapy in Parkinson's disease are strongly focused
on the dopamine system, with the view that restoring dopaminergic inputs in a localized and …

Current therapies for Parkinson's disease are symptomatic and unable to regenerate the
brain tissue. In recent years, the therapeutic potential of a wide variety of neuroprotective …